A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Rumana Alim1*, Sofia Andalib Safiullah1, Shaila Munwar1, Ishad Mazhar1, Sifat Uz Zaman2, MD. Sarwar Bari3
1 Department of Microbiology, Medical College for Women and Hospital, Dhaka, Bangladesh
2 Infection Prevention and Control Division, Medlife Healthcare Limited, Dhaka, Bangladesh
3 Department of Printing & Publications, Dhaka, Bangladesh
Email: ★该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
How to cite this paper: Alim, R., Safiullah, S.A., Munwar, S., Mazhar, I., Zaman, S.U. and Bari, M.S. (2022) Wound Infection Caused by Chromobacterium violaceum: A Case Report from a Tertiary Care Hospital in Bangladesh. Advances in Microbiology, 12, 83-89.
Received: January 17, 2022
Accepted: February 21, 2022
Published: February 24, 2022
Copyright © 2022 by author(s) and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
http://creativecommons.org/licenses/by/4.0/
https://doi.org/10.4236/aim.2022.122007
Chromobacterium violaceum is a Gram negative, facultative anaerobe, generally present in water, soil in tropical and subtropical regions. This bacterium is an emerging environmental pathogen that causes life threatening infection in humans and animals. It can cause wound infection, visceral abscess, septicaemia, meningitis, diarrhoea, UTI. It is associated with significant mortality due to severe systemic infection. As the bacteria have high spreading tendency leading to sepsis, early identification and prompt treatment is necessary. Here we report a case of Chromobacterium violaceum wound infection in a 9 years old male from Dhaka, who was successfully treated with combination of cefixime and flucloxacillin antibiotics as per culture sensitivity report.
Keywords
Chromobacterium violaceum, Wound Infection, Antibiotics
A mobile application for wound care (Minuteful) was trailed over a seven-month period in an acute inpatient setting in Northwest England. During the trial an increase in the availability of wound photography was noted (+37%), a reduction in inappropriate tissue viability nurse reviews (-10%) and the identification of mis-reported pressure ulcers (n=65). Challenges noted during the implementation included initial software compatibility issues with the tablets available on the wards and poor staff engagement. Overall, this initial trial indicates the potential safety, economic and service efficiency improvements that may be possible via implementation of mobile application technology in wound care. Further robust studies are needed to explore the initial findings of this trial in greater depth.
KEY WORDS: Acute care Chronic wounds Mobile application Wound care
MATTHEW WYNN
Honorary Tissue Viability Nurse- Northern Care Alliance NHS Foundation Trust' LUCY SCHOLES Senior Tissue Viability Nurse, Northern Care Alliance NHS Foundation Trust 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Emily R. Kindal1, Kaitlin J. Larson2, Luis G. Fernandez3,4,5#, Sean F. O’Keefe6, Marc R. Matthews7*
1 Medical Student IV, Royal College of Surgeons in Ireland, Dublin, Ireland
2 Surgical Resident, The Arrowhead Surgical Residency, Glendale, Arizona
3 Department of Surgery, University of Texas Health Science Center, Tyler, USA
4 Trauma Wound Care, UT Health East, Tyler, USA
5 Department of Surgery, University of Texas Medical Branch, Galveston, USA
6 Business Development Manager, Saint Paul, US
7 University of Arizona & Creighton University Schools of Medicine, The Arizona Burn Center, Phoenix, Arizona
Email:★marc_该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.
How to cite this paper: Kindal, E.R., Larson, K.J., Fernandez, L.G., O’Keefe, S.F. and Matthews, M.R. (2022) The Use of the V.A.C. RX-4 for Multiple Soft Tissue Wound Application in the Single Patient: A Case Report. Surgical Science, 13, 155-163. https://doi.org/10.4236/ss.2022.133020
Received: January 28, 2022
Accepted: March 26, 2022
Published: March 29, 2022
Copyright © 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/
Contact burn injuries account for a considerable proportion of admissions that frequently require debridement. Such debridements of these multiple open wounds might benefit from the application of negative pressure wound therapy (NPWT) for the removal of proinflammatory mediators and to promote granulation tissue with macrostrain and microstrain. Having four or more Vacuum Assist Closure (V.A.C.) Ulta devices connected to the same patient for adequate wound coverage is cumbersome in the management of the patient’s wound care and tethers the patient to the bed. The V.A.C. RX-4 is a multichannel device that can deliver NPWT with a smaller footprint. In addition, the V.A.C. RX-4 has a weight of 16 lbs. versus one V.A.C Ulta which is 7.4 lbs. Therefore, collectively, four V.A.C. Ultas would equal 29.6 lbs. or almost double the weight of a single V.A.C. RX-4. Use of the V.A.C. RX-4 by healthcare providers can mean greater mobility for the patient and easier transport between patient destinations within the hospital. This case report demonstrates the utility of the V.A.C. RX-4 for open and freshly debrided, large soft tissue wounds in a burn patient.
# UT Texas, Assistant Clinical Professor of Surgery/Family Practice UT Health North East, Tyler, Texas, Adjunct Clinical Professor of Medicine and Nursing, University of Texas, Arlington, Texas, Past Commanding General TXSG Medical Brigade, Austin, TX USA, Chairman Emeritus, Division of Trauma Surgery/Surgical Critical Care, Associate Trauma Medical Director and Chief of Trauma Surgical Critical Care Unit, Christus Trinity Mother Frances Health System, Tyler, Texas, Surgical Attending, Adjunct Associate Professor, University of North Texas, Denton, Texas.
V.A.C. RX-4, Negative Pressure Wound Therapy, Wounds, V.A.C. Ulta, Footprint, Burns
Nanotechnology has opened a new area of scientific research. This field deals with materials within the dimensions of 1–100nm and a plethora of new technologies have emerged. In wound care, silver nanoparticles are used to aid wound healing as an antimicrobial agent, but also as an anti-inflammatory agent. The properties of silver nanoparticles differ from that of the material on a larger scale and their production can be controlled to give varied properties and characteristics that have different uses. These resultant properties are very important and differences in characterisation can alter their biological and physical attributes. All wound dressings have to undergo rigorous scrutiny around toxicity and safety when regulatory review is undertaken, yet some users still have concerns over long-term effects of silver nanoparticles in vivo. This review will address some of these concerns and reviews the current health and safety data associated with introduction of new products containing silver nanoparticles using Venus Ag dressings (SFM LTD, UK) as an example.
KEY WORDS Nanoparticles of silver Safety Silver dressings Toxicity
VAL EDWARDS-JONES PhD,CSci, FIBMS, Independent Microbiology Consultant, Essential Microbiology Limited
There were an estimated 3.8 million patients with a wound managed by the NHS in 2017/2018 at a cost of £8.3 billion (Guest et al, 2017). The cost to the patient and their quality of life is immense. Evidence has shown that there are wide variations in the care of people with chronic wounds, with many patients not receiving the correct assessment or a diagnosis on which to base decisions about their care (Guest et al, 2015; Gray et al, 2018). Delivering efficient and effective care to patients with a venous leg ulcer (VLU) requires collaborative working across specialist and community settings to tackle inequalities in care, improve outcomes, enhance productivity, and provide value for money.
KEY WORDS Venous leg ulcer Compression Reducing variation UrgoKTwo DR CAROLINE DOWSETT Clinical Nurse Specialist Tissue Viability, East London NHS Foundation Trust; Independent Nurse Consultant
ABSTRACT: Biofilm formation in wounds contributes greatly to the lack of healing and increased healthcare expenditures. Antimicrobial efficacy is decreased significantly in the presence of biofilms, which can, in turn, promote the development of antibiotic resistance. Antibiofilm strategies to prevent the formation and persistence of biofilm in wounds would consequently decrease the incidence of chronic wounds and improve wound healing. The use of preclinical biofilm models to assess the antibiofilm efficacy of wound dressings is a prerequisite to identifying new technologies that can improve outcomes in hardto-heal wounds. Improvements to preclinical approaches (in vitro and in vivo) to biofilm models are needed. Living tissue (ex vivo) derived from pig and human skin donors is a developing approach that translates the research to the clinic, including the native microenvironment of the biofilm.
KEY WORDS Bacteria Biofilm Infection Microbiology Swab Wound dressings
MARNIE PETERSON PharmD, PhD, Site Director, Perfectus Biomed Group, Now Part of NAMSA, 3545 South Park Dr., Jackson, Wyoming, 83001, US. 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
SAM WESTGATE PhD, Executive Director, Perfectus Biomed Group, Now Part of NAMSA, Techspace One SciTech Daresbury, Keckwick Lane, Daresbury, Cheshire, WA4 4AB, UK, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。